KRON Stock Summary and Trading Ideas (Kronos Bio | NASDAQ:KRON)

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Kronos Bio trades on the NASDAQ stock market under the symbol KRON.

As of March 3, 2025, KRON stock price declined to $0.93 with 323,823 million shares trading.

KRON has a beta of 0.79, meaning it tends to be less sensitive to market movements. KRON has a correlation of 0.02 to the broad based SPY ETF.

KRON has a market cap of $55.77 million. This is considered a Micro Cap stock.

Last quarter Kronos Bio reported $2 million in Revenue and -$.23 earnings per share. This beat revenue expectation by $270,000 and exceeded earnings estimates by $.05.

In the last 3 years, KRON traded as high as $8.42 and as low as $.69.

The top ETF exchange traded funds that KRON belongs to (by Net Assets): VTI, VXF, IWC.

KRON has underperformed the market in the last year with a price return of -24.8% while the SPY ETF gained +16.7%. KRON has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.7% and -9.3%, respectively, while the SPY returned -2.2% and -4.3%, respectively.

KRON support price is $.95 and resistance is $1.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRON shares will trade within this expected range on the day.